Skip to main content
    I

    ICU Medical Inc (ICUI)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $181.87
    +2.60 (+1.45%)

    Market Cap: $4.48B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ICU Medical Inc (ICUI) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    ICU Medical (ICUI) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, ICU Medical reported EPS of $2.11, above the $1.75 estimate. It beat the EPS estimate in each of the last 17 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    93%(37/40)
    Avg Surprise
    +30.78%
    Streak
    17 Q

    Upcoming Estimates

    Reports Feb 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.21
    Range$2.08 - $2.38
    9 analysts
    Revenue Consensus
    $570.49M
    Range$543.70M - $594.93M
    9 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.14
    Range$2.10 - $2.16
    4 analysts
    EPS Revisions
    4
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$2.15-0.6%
    60d ago$2.15-0.6%
    30d ago$2.15-0.6%
    7d ago$2.15-0.6%
    Current$2.14
    Revenue Consensus
    $545.50M
    Range$543.30M - $548.40M
    3 analysts

    Next Report

    ICUI has an expected report date of Feb 17, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 15.7% above the $1.91 reported for the quarter ended Dec 31, 2025.

    ICUI Earnings Call

    The latest ICUI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ICUI beat 37 and missed 3. Revenue for the quarter ended Sep 30, 2026 was $560.44M, up 4.4% from $536.99M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.11$1.75N/A+20.57%Beat+3.9%76 up, 1 downNov 5, 2026$560.44M
    Jun 30, 2026$2.01$1.49N/A+34.90%Beat+21.1%71 up, 0 downAug 6, 2026$551.68M
    Mar 31, 2026$1.97$1.75$1.66 - $1.91+12.57%Beat+14.5%60 up, 3 downMay 7, 2026$530.23M
    Dec 31, 2025$1.91$1.69$1.64 - $1.77+13.02%Beat-9.5%61 up, 0 downFeb 19, 2026$540.70M
    Sep 30, 2025$2.03$1.43$1.17 - $1.58+41.96%Beat+27.7%61 up, 3 downNov 6, 2025$536.99M
    Jun 30, 2025$1.66$1.14N/A+45.61%Beat+6.4%52 up, 3 downAug 7, 2025$548.87M
    Mar 31, 2025$1.72$1.28$1.17 - $1.44+34.38%Beat+79.2%51 up, 1 downMay 8, 2025$604.70M
    Dec 31, 2024$2.11$1.48$1.42 - $1.54+42.38%Beat+34.4%52 up, 0 downFeb 27, 2025$629.80M
    Sep 30, 2024$1.59$1.25$1.13 - $1.36+27.20%Beat+1.3%60 up, 0 downNov 12, 2024$589.13M
    Jun 30, 2024$1.56$1.00$0.88 - $1.07+56.00%Beat-17.0%50 up, 0 downAug 7, 2024$596.46M
    Mar 31, 2024$0.96$0.82$0.76 - $0.89+17.07%Beat-44.8%40 up, 0 downMay 7, 2024$566.65M
    Dec 31, 2023$1.57$1.19$1.13 - $1.24+31.93%Beat-1.9%40 up, 0 downFeb 27, 2024$587.86M
    Sep 30, 2023$1.57$1.39$1.29 - $1.48+12.95%Beat-10.3%20 up, 0 downNov 6, 2023$553.31M
    Jun 30, 2023$1.88$1.60$1.45 - $1.70+17.50%Beat+37.2%30 up, 0 downAug 7, 2023$549.31M
    Mar 31, 2023$1.74$1.43$1.36 - $1.53+21.68%Beat-4.4%30 up, 0 downMay 8, 2023$568.65M
    Dec 31, 2022$1.60$1.56$1.43 - $1.69+2.56%Beat-12.1%30 up, 0 downFeb 27, 2023$578.01M
    Sep 30, 2022$1.75$1.46$1.37 - $1.57+19.86%Beat-15.5%30 up, 0 downNov 7, 2022$597.86M
    Jun 30, 2022$1.37$1.66N/A-17.47%Miss-27.1%30 up, 0 downAug 8, 2022$561.00M
    Mar 31, 2022$1.82$1.78$1.73 - $1.85+2.25%Beat+12.3%30 up, 0 downMay 9, 2022$543.12M
    Dec 31, 2021$1.82$1.64$1.61 - $1.68+10.98%Beat+2.8%30 up, 0 downFeb 24, 2022$340.52M
    Sep 30, 2021$2.07$1.80$1.76 - $1.82+15.00%Beat+8.9%30 up, 0 downNov 3, 2021$336.06M
    Jun 30, 2021$1.88$1.64$1.61 - $1.66+14.63%Beat+13.9%3N/AAug 4, 2021$321.68M
    Mar 31, 2021$1.62$1.50$1.46 - $1.54+8.00%Beat-10.5%3N/AMay 6, 2021$318.05M
    Dec 31, 2020$1.77$1.51$1.44 - $1.58+17.22%Beat-8.8%3N/AFeb 25, 2021$320.45M
    Sep 30, 2020$1.90$1.31$1.16 - $1.40+45.04%Beat+15.2%3N/ANov 5, 2020$318.57M
    Jun 30, 2020$1.65$1.24$1.05 - $1.35+33.06%Beat-17.1%3N/AAug 10, 2020$303.38M
    Mar 31, 2020$1.81$1.63$1.56 - $1.69+11.04%Beat-29.8%3N/AMay 7, 2020$328.61M
    Dec 31, 2019$1.94$1.66$1.57 - $1.66+16.87%Beat-6.3%3N/AFeb 27, 2020$315.52M
    Sep 30, 2019$1.65$1.62$1.57 - $1.66+1.85%Beat-10.8%3N/ANov 11, 2019$307.47M
    Jun 30, 2019$1.99$2.06$2.00 - $2.09-3.40%Miss-25.2%3N/AAug 7, 2019$312.28M
    Mar 31, 2019$2.58$2.17$2.11 - $2.27+18.89%Beat+14.2%3N/AMay 9, 2019$330.93M
    Dec 31, 2018$2.07$1.80$1.72 - $1.88+15.00%Beat-30.5%3N/AFeb 28, 2019$340.38M
    Sep 30, 2018$1.85$1.51$1.32 - $1.63+22.52%Beat+65.2%3N/ANov 8, 2018$327.17M
    Jun 30, 2018$2.66$1.82$1.80 - $1.85+46.15%Beat+250.0%3N/AAug 9, 2018$360.46M
    Mar 31, 2018$2.26$1.84$1.77 - $1.90+22.83%Beat+34.5%3N/AMay 9, 2018$372.03M
    Dec 31, 2017$2.98$1.04$0.92 - $1.15+186.54%Beat+148.3%3N/AMar 1, 2018$370.12M
    Sep 30, 2017$1.12$0.76$0.68 - $0.84+47.37%Beat-17.0%3N/ANov 9, 2017$343.24M
    Jun 30, 2017$0.76$0.77$0.65 - $0.88-1.30%Miss-33.9%3N/AAug 9, 2017$331.51M
    Mar 31, 2017$1.68$0.46N/A+265.22%Beat+47.4%N/AN/AMay 10, 2017$247.74M
    Dec 31, 2016$1.20$1.19N/A+0.84%Beat+25.0%N/AN/AMar 1, 2017$95.69M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $7.32, up 17.7% from the year before. It was $4.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$7.32+17.7%
    Dec 31, 2024$6.22-8.0%
    Dec 31, 2023$6.76+3.4%
    Dec 31, 2022$6.54-11.5%
    Dec 31, 2021$7.39+3.6%
    Dec 31, 2020$7.13-12.6%
    Dec 31, 2019$8.16-7.7%
    Dec 31, 2018$8.84+35.2%
    Dec 31, 2017$6.54+35.1%
    Dec 31, 2016$4.84N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,600 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,64110
    2026Q2Jun 30, 20266,18310
    2026Q1Mar 31, 20265,96310
    2025Q4Dec 31, 20257,4059
    2025Q3Sep 30, 20255,8269
    2025Q2Jun 30, 20255,6068
    2025Q1Mar 31, 20256,1229
    2024Q4Dec 31, 20246,1919

    2026Q3 Earnings Call

    Opening remarks

    Deirdre Thomson ICR Senior Vice President Thank you for joining us to discuss ICU Medical's financial results for the third quarter of 2026. On the call today representing ICU Medical are Vivek Jain, Chief Executive Officer and Chairman, and Brian Bonnell, Chief Financial Officer. We wanted to let everyone know that we have a presentation to accompany today's prepared remarks. To view the presentation, please go to our Investor page and click on Events Calendar, and it will be under third quarter 2026 events. Before we start our prepared remarks, we want to touch upon any forward-looking statements made during the call, including beliefs and expectations about the company's future results. Please be aware they are based on the best available information to management and assumptions that are reasonable. Such statements are not intended to be a representation of future results and are subject to risks and uncertainties. Future results may differ materially from management's current expectations. We refer all of you to the company's SEC filings for more detailed information on the risks and uncertainties that have a direct bearing on operating results and financial position. Please note that during today's call, we will also discuss non-GAAP financial measures, including results on an adjusted basis. We believe these financial measures can facilitate a more complete analysis and greater transparency into ICU Medical's ongoing results of operations, particularly when comparing underlying results from period to period. We've also included a reconciliation of these non-GAAP measures in today's release and provide as much detail as possible on any addendums that are added back. And with that, it is my pleasure to turn the call over to Vivek.

    Vivek Jain CEO and Chairman Thanks, Deirdre, and good afternoon, everyone. I'll walk through our Q3 revenue and earnings performance and provide some color on the businesses, and then turn it over to Brian, who will recap the full Q3 results. After that, I'll come back with a few updates on product development initiatives and some comments on our performance against our near- and midterm financial goals and our latest capital allocation strategy. Revenue for Q3 was $556 million for total company growth of 5% on an organic basis or 4% reported, as the reported results are no longer impacted by the mid-2025 creation of the Otsuka ICU Medical joint venture and the resulting deconsolidation of IV solutions from our income statement. Adjusted gross margins were strong at just over 42%. Adjusted EBITDA improved to $114 million and adjusted EPS was $2.44. Organic free cash flow was again healthy. And when combined with tariff refunds, which are excluded from our P&L commentary today, we were able to repay approximately $80 million of debt in the quarter and will finish 2026 slightly below 2x net leverage.

    Frequently Asked Questions About ICUI

    When is ICU Medical's next earnings date?

    ICU Medical's next earnings report is expected for Feb 17, 2027.

    Did ICUI beat earnings estimates last quarter?

    Yes. ICU Medical reported EPS of $2.11 for the quarter ended Sep 30, 2026, above the $1.75 estimate, a 20.57% surprise.

    What EPS do analysts expect from ICUI next quarter?

    The consensus EPS estimate for ICU Medical for the quarter ending Dec 31, 2026 is $2.21 from 9 analysts, with estimates from $2.08 to $2.38.

    How often does ICUI beat earnings estimates?

    ICU Medical beat the EPS estimate in each of the last 17 quarters, with an average surprise of +26.60%.